Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
Lorigan, Paul C
Linch, David C
Sweetenham, J W
Johnson, Peter W
AffiliationCancer Research UK Clinical Centre, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, UK.
MetadataShow full item record
AbstractGranulocyte colony-stimulating factor (G-CSF) is widely used following myeloablative chemotherapy (high-dose therapy; HDT) and peripheral blood progenitor cell rescue (PBPCR) to reduce neutrophil engraftment time. The dose and duration required to gain maximum clinical and economic benefit has not been fully investigated. This double blind placebo-controlled randomised trial was performed to determine whether short course low-dose or standard-dose Lenograstim (L) would influence recovery of haematopoiesis following HDT and PBPCR. Sixty-one patients were randomised between May 1999 and November 2004, to receive standard-dose lenograstim (263 microg/d), low-dose lenograstim (105 microg/d) or placebo injections. These commenced on day +5 following PBPCR and continued until neutrophil engraftment [absolute neutrophil count (ANC)] > or = 0.5 x 10(9)/l. Patients received standard supportive care until haemopoietic recovery. Both standard- and low-dose lenograstim resulted in a significantly shorter median time to neutrophil recovery (ANC > or = 0.1 x 10(9)/l:10.0 vs. 11.0 d, P = 0.025; ANC > or = 0.5 x 10(9)/l:11.0 vs. 14.0 d, P = 0.0002) compared with placebo. There was no significant difference in blood product support, antibiotic usage, documented infection, overall survival or relapse-free survival between the groups. Short course low-dose lenograstim is as effective as standard-dose in reducing neutrophil engraftment time following HDT and PBPCR.
CitationLow-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. 2007, 137 (5):436-42 Br. J. Haematol.
JournalBritish Journal of Haematology
- Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
- Authors: Jang G, Ko OB, Kim S, Lee DH, Huh J, Suh C
- Issue date: 2008 Apr
- Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy.
- Authors: Kim IH, Park SK, Suh OK, Oh JM
- Issue date: 2003
- Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses.
- Authors: Suh C, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, Kim EK, Kim SB, Lee JS, Kim MW, Kim K, Yoon SS
- Issue date: 2004 Apr
- Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial.
- Authors: Schmitz N, Ljungman P, Cordonnier C, Kempf C, Linkesch W, Alegre A, Solano C, Simonsson B, Sonnen R, Diehl V, Fischer T, Caballero D, Littlewood T, Noppeney R, Schafhausen P, Jost L, Delabarre F, Marcus R
- Issue date: 2004 Dec
- Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
- Authors: Takemoto Y, Wada H, Takatsuka H, Okamoto T, Kakishita E
- Issue date: 2000